Ischemic Stroke
Conditions
Brief summary
This is a 50-patient, Phase 2, double-blind, randomized, placebo-controlled, hybrid decentralized study to evaluate the safety and efficacy of daily subcutaneous (SC) injection of TXA127 in post-ischemic stroke patients. Subjects will receive either TXA127 0.5mg/kg or placebo for 12 weeks started 6 to 24 months post ischemic stroke, and they will have a 12 week follow up visit after treatment has ended. The primary efficacy outcome measure is individual patient absolute change from baseline in motor and sensory functions as measured by the Fugl-Meyer Assessment of Upper Extremity (FMA-UE) 12 weeks after start of treatment.
Detailed description
This is a safety, tolerability, and efficacy study in patients with sensorimotor deficits after confirmed middle cerebral artery ischemic stroke. The study will be double-blinded and placebo-controlled and conducted over a period of approximately 6 months, with treatment starting 6-24 months after stroke. After obtaining informed consent, eligibility will be determined by review of medical history and assessments of patient's condition. To establish a baseline, all assessments will be completed prior to administration of the first dose of study drug. Patients will be randomized (1:1) to receive either subcutaneous (SC) placebo or TXA127 (0.5 mg/kg) injections once daily for 12 weeks. In addition to receiving either the study drug or placebo, patients will be required to undergo physical therapy (PT) or occupational therapy (OT) at least twice a week. Patients will be followed up for 12 weeks after end of treatment. Throughout the study, study visits will be conducted at the medical center and the patient's home. At certain planned study visits, patients will undergo a brief physical examination, and blood will be drawn for safety evaluation and for measuring biomarkers. At the Screening, Week 12, and Week 24 visits, patients will rate their disability and health-related quality of life using the Stroke Impact Scale. In addition, upper and lower extremity motor and sensory function (FMA-UE/LE), and gait velocity (Timed Up and Go) will be evaluated. Patients will be asked to report of any safety events throughout the study and follow up period.
Interventions
DRUGtalfirastide
TXA127, a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II) is a sterile solution containing angiotensin (1-7) \[A(1-7)\], supplied in a 3 mL, single-use, stoppered vial.
DRUGPlacebo
Placebo is a sterile solution containing supplied in a 3 mL, single-use, stoppered vial.
Sponsors
Constant Therapeutics LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Age: 18-85 years 2. BMI: 18.0-35.0 kg/m2 3. Patient suffered an ischemic stroke (caused by blockage of the middle cerebral artery) 6-24 months prior to enrollment and with no additional symptomatic stroke incidents since then. 4. Patient resides in Israel between Hedera and Gedera 5. Fugl-Meyer Assessment of Upper Extremity: 20-50 without reflex items 6. Patient suffers from hemiparesis as assessed by the study investigator 7. Premorbid disability does not impact physical and cognitive function to a degree that would limit completion of study activities and assessments, as assessed by the study investigator 8. Patient agrees to participate in two physical therapy or occupational therapy sessions per week 9. Patient is able to use a device for telemedicine meetings with a physician and to record study-related events in an electronic diary, either alone or with caregiver's assistance
Exclusion criteria
1. Woman of childbearing potential who is pregnant or planning to become pregnant, or not using birth control 2. Aphasia or dementia limiting ability of patient to comply with instructions as assessed by the study investigator 3. Current diagnosis of severe depression (NOTE: In case of doubt, a patient who is currently taking or has taken within the last 30 days second-line anti-depressants OR who has scored 12-15 points using the Geriatric Depression Scale, will be considered severely depressed and will not be eligible to participate in the study.) 4. Drug or alcohol abuse within the last year 5. Current or planned Botox administration for upper limb spasticity, strabismus, overactive bladder, migraine prevention, blepharospasm, cervical dystonia or other off-label uses including but not limited to: sialorrhea, post-herpetic neuralgia, Raynaud's disease, achalasia, or any use the investigator believes may interfere with an accurate neurological exam. Permitted uses - cosmetic (wrinkles), hyperhidrosis 6. Participation in a transcranial magnetic stimulation and/or other interventional stroke studies within 6 months of screening 7. History of cancer within three years of screening, with the exception of fully excised non-melanoma skin cancers or non-metastatic prostate cancer that has been stable for at least 6 months 8. Any medical condition that, in the opinion of the investigator, would preclude patient participation in the study and/or analysis of results 9. Significant disability prior to stroke that would impact execution of any of the functional assessments in the protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | 12 weeks | Incidence of adverse events (AEs) assessed according to CTCAE v5.0 |
| Fugl-Meyer Assessment of Upper Extremity (FM-UE) | 12 weeks | Individual patient absolute change from baseline in motor and sensory functions as measured by the Fugl-Meyer Assessment of Upper Extremity (FMA-UE) 12 weeks after start of treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time Up and Go | 12 weeks | Percent change from baseline gait velocity as measured by Timed Up and Go 12 weeks after start of treatment |
| Stroke Impact Scale | 12 weeks | Absolute change from patient's baseline self-assessment as measured by Stroke Impact Scale 12 weeks after start of treatment, scored 0 to 100 with higher scores indicating higher quality of life |
| Durability of Time Up and Go | 24 weeks | Percent change in gait velocity as measured by Timed Up and Go |
| Durability of Stroke Impact Scale | 24 weeks | Absolute change in patient self-assessment as measured by Stroke Impact Scale over the 12-week follow-up period (12-24 weeks after the start of treatment); scored 0 to 100 with higher scores indicating higher quality of life |
| Durability of Fugl-Meyer | 24 weeks | Absolute change in motor and sensory function as measured by the Fugl-Meyer Assessment of Upper and lower Extremity (FMA-UE & FMA-LE) |
| Fugl-Meyer Assessment of Lower Extremity (FMA-LE) | 12 weeks | Individual patient absolute change from baseline in motor and sensory functions as measured by the Fugl-Meyer Assessment of Lower Extremity (FMA-LE) 12 weeks after start of treatment. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Neurofilament light chain (NfL) | 12 weeks | change in serum neurofilament light chain |
| Brain-derived neurotrophic factor (BDNF) | 12 weeks | change in serum brain-derived neurotrophic factor |
Countries
Israel
Contacts
Primary ContactRichard L Franklin, MD, PhD
Backup ContactElizabeth Wagner, MS, MBA
Outcome results
None listed